FDA Approves Tyvaso (treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
FDA Approves Tyvaso (treprostinil) Inhalation Solution for the
Treatment of Pulmonary Arterial Hypertension
July 30, 2009
SILVER SPRING, Md., July 30 /PRNewswire-FirstCall/ -- United
Therapeutics Corporation announced today that the United States Food
and Drug Administration (FDA) has approved Tyvaso (treprostinil)
Inhalation Solution for the treatment of pulmonary arterial
hypertension (PAH) using the Tyvaso Inhalation System (which includes
the Optineb-ir device and accessories). Tyvaso is indicated to
increase walk distance in patients with NYHA Class III symptoms
associated with WHO Group I PAH
Treatment of Pulmonary Arterial Hypertension
July 30, 2009
SILVER SPRING, Md., July 30 /PRNewswire-FirstCall/ -- United
Therapeutics Corporation announced today that the United States Food
and Drug Administration (FDA) has approved Tyvaso (treprostinil)
Inhalation Solution for the treatment of pulmonary arterial
hypertension (PAH) using the Tyvaso Inhalation System (which includes
the Optineb-ir device and accessories). Tyvaso is indicated to
increase walk distance in patients with NYHA Class III symptoms
associated with WHO Group I PAH
Comentarios
Publicar un comentario